UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Q4 / FY 2023 Results | February 22, 2024 This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance including operating and profit margins for 2024 and its medium- and long-term growth outlook; assumptions regarding expected changes in market share and expectations regarding the extent and impact of competition; assumptions regarding future exchange rates; strategic priorities, s ...

February 22, 2024 Strong Underlying Financial Performance and Execution Against Strategic Priorities in 2023 Comment by Mark Crossley, CEO of Indivior PLC "At our December 2022 Capital Markets Day, we laid out Indivior's strategy and medium term financial goals targeting double-digit top line growth, operating margin expansion and strengthened cash flow. By executing against our strategic priorities, we delivered strongly against these goals in 2023. We grew SUBLOCADE and PERSERIS® net revenue by 54% and 50 ...

• INDV 2000 (OUD3): Phase 1 study MAD6 LSLV in Q3-2023, Successful endof-Phase 1 meeting with FDA in Q4- 20235 • INDV 4002 (AUD3): Phase 2 data Q4- 20235 Q3 2023 financial highlights Key Takeaways (vs. Q3 2022) ➤ Reported SG&A expenses driven by litigation provision; Adjusted SG&A expenses up 33% reflecting increased legal costs, Opiant and OPVEE launch expenses, SUBLOCADE commercial investments and cost inflation 2 See reconciliation pages in the appendix 3 Actual FX (foreign exchange) rates Cash & Borrowi ...

November 9, 2023 Strong Top-line Performance and Strategic Progress in Q3 2023 • FY 2023 SUBLOCADE NR now expected to be $610m to $630m (vs. $590m to $630m) • OPVEE® launched; U.S. Biomedical Advanced Research and Development Authority (BARDA) contract secured Period to September 30th (Unaudited) Q3 2023 $m Q3 2022 $m % Change YTD 2023 $m YTD 2022 $m % Change Net Revenue 271 232 17% 800 659 21% Operating (Loss)/Profit (183) 56 NM (65) 173 NM Net (Loss)/Income (135) 41 NM (52) 130 NM Diluted (LPS)/EPS ($) $( ...

Indivior PLC (INVVY) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Officer Ryan Preblick - Chief Financial Officer Conference Call Participants James Vane-Tempest - Jefferies Max Herrmann - Stifel Paul Cuddon - Numis Securities Thibault Boutherin - Morgan Stanley Karl Burns - Northland Capital Markets Edward Thomason - Liberum Peter Testa - On ...

Q2/H1 2023 Results July 27, 2023 Important cautionary statement regarding forward-looking statements 2 This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding: expectations regarding the cost to resolve the Group's legal proceedings and regulatory matters; strategies for value creation and operational goals; expected sales levels for particular products; product development pipeline and potential future products; ex ...

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated by the Market Abuse Regulation (EU) No.596/2014, as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain. July 27, 2023 Strong H1 and Q2 2023 Financial Results; FY 2023 Guidance Raised • Q2 2023 SUBLOCADE® Net Revenue (NR) of $155m, +58% versus ...

Thank you for taking my questions. Three, please. The first one on litigation. The press release mentioned that new offers and demands have been exchanged with the state in the context of the MDL litigation. So just curious to know why the states have been singled out here? What about the other classes of [indiscernible] purchasers and payers, which are also involved in the MDL? Is there any reason why they have been excluded from these additional exchanges? So that's the first question. Second one, on the ...

Important cautionary statement regarding forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance for 2023 and its medium- and long-term growth outlook; strategies for value creation; expectations for sales levels for particular products; expectations regarding the cost to resolve the Group's legal proceedings and regulatory matters; the timing of our ...